headquart san diego california
pure play diabet compani focus continu
reason report
estim chang analysi sales/earn
reiter o/v invest rate price target
share follow compani report oper
result rais guidanc importantli signific
top-lin beat highlight compani abil drive top tier
organ revenu growth despit competit channel geograph
mix challeng result technolog leadership
cgm market moreov compani oper margin
temporarili burden higher manufactur cost transit
pharmaci benefit channel stand benefit new lower
cost transmitt compani expect achiev
approxim gross margin exit year lastli
plan new product pipelin remain on-track accordingli
market penetr growth acceler margin
mend reiter o/v invest rate price
target share
maintain price maintain per
revenu multipl approxim
increas estim increas former
billion revenu estim billion reduc former
earn estim per share
conserv maintain billion revenu estim
increas former earn estim per
annual revenu guidanc million million
revis rang million million pre-cal
consensu million addit compani moder
gross margin guidanc approxim rang
modestli increas non-gaap oper margin
guidanc reiter non-gaap ebitda
margin goal
rel valuat review share current trade
revenu versu compar industri peer trade
like multipl view rel premium warrant base
top-tier organ growth outlook within larg modestli
penetr technolog leadership strong new product
cadenc expand margin profil
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
oper highlight oper period total revenu million pre-cal consensu
million increas specif domest sale increas year year million
intern sale growth remain strong increas year year million dxcm quarterli gross
margin declin year year pre-cal consensu result previous mention
manufactur invest increas capac compani shift pharmaci benefit model compani
report non-gaap oper margin oper period versu oper
period result report adjust ebitda million equival sale net loss
million per share includ million busi transit relat cost million
non-cash interest expens million loss relat equiti invest adjust million busi
transit relat cost million non-cash interest expens million loss relat equiti invest
compani report non-gaap earn loss per share oper period
balanc sheet review exit oper period million cash cash equival
million debt net cash posit million equival net cash per share
perspect competit concern continu introduc volatil valuat import keep
absolut size address also absolut low market penetr mind end recal
estim compani penetr domest type intens popul estim
global penetr rate relat cgm devic still look share remain
volatil enter american diabet associ ada annual meet june street await expect
immin fda approv libr encourag investor continu build posit anticip
street focu return compani long-term growth prospect post ada
look ahead look balanc follow event stand serv potenti
posit catalyst enhanc growth margin profil preview tandem rate
idcl data upcom ada highlight combin pump cgm offer
dxcm/type zero algorithm singl hybrid closed-loop system roll-out compani new low cost
transmitt associ reduct relat cog versu exist transmitt doubl
product capac commerci launch enhanc function industry-lead
offer estim late earli launch compani much anticip next gener
cgm platform
dollar thousand except per share data
revenu
fiscal period
fiscal period
research develop
sell gener administr
research develop
sell gener administr
research develop
compani report stephen inc estim
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
